Evidence map›Paper›PMID 22894956›Full record

ArticleHuman vaccines & immunotherapeutics2012

IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques.

Rashmi Jalah, Vainav Patel, Viraj Kulkarni, Margherita Rosati, Candido Alicea, Brunda Ganneru, Agneta von Gegerfelt, Wensheng Huang, Yongjun Guan, Kate E Broderick and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 74 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Development of synthetic antigen vaccines for COVID-19.Human vaccines & immunotherapeutics · 2021
    Review
  12. Article
  13. Review
  14. Article
  15. Polymeric Nanoparticle-Based Vaccine Adjuvants and Delivery Vehicles.Current topics in microbiology and immunology · 2021
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Rashmi JalahHuman Retrovirus Pathogenesis Section; Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Vainav Patel
Viraj Kulkarni
Margherita Rosati
Candido Alicea
Brunda Ganneru
Agneta von Gegerfelt
Wensheng Huang
Yongjun Guan
Kate E Broderick
Niranjan Y Sardesai
Celia LaBranche
David C Montefiori
George N Pavlakis
Barbara K Felber
Frederick National Laboratory for Cancer Research · USDuke Medical Center · USInovio Pharmaceuticals (United States) · USUniversity of Maryland, Baltimore · US

Funding

Prevention of AIDSZIABC010350 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FELBER, BARBARA K · 2009 to 2025
$30.0M
Intramural NIH HHS
6 · The paper itself

Abstract

Intramuscular injection of macaques with an IL-12 expression plasmid (0.1 or 0.4 mg DNA/animal) optimized for high level of expression and delivered using in vivo electroporation, resulted in the detection of systemic IL-12 cytokine in the plasma. Peak levels obtained by day 4-5 post injection were paralleled by a rapid increase of IFN-γ, indicating bioactivity of the IL-12 cytokine. Both plasma IL-12 and IFN-γ levels were reduced to basal levels by day 14, indicating a short presence of elevated levels of the bioactive IL-12. The effect of IL-12 as adjuvant together with an SIVmac239 DNA vaccine was further examined comparing two groups of rhesus macaques vaccinated in the presence or absence of IL-12 DNA. The IL-12 DNA-adjuvanted group developed significantly higher SIV-specific cellular immune responses, including IFN-γ (+) Granzyme B (+) T cells, demonstrating increased levels of vaccine-induced T cells with cytotoxic potential, and this difference persisted for 6 mo after the last vaccination. Coinjection of IL-12 DNA led to increases in Gag-specific CD4 (+) and CD4 (+) CD8 (+) double-positive memory T cell subsets, whereas the Env-specific increases were mainly mediated by the CD8 (+) and CD4 (+) CD8 (+) double-positive memory T cell subsets. The IL-12 DNA-adjuvanted vaccine group developed higher binding antibody titers to Gag and mac251 Env, and showed higher and more durable neutralizing antibodies to heterologous SIVsmE660. Therefore, co-delivery of IL-12 DNA with the SIV DNA vaccine enhanced the magnitude and breadth of immune responses in immunized rhesus macaques, and supports the inclusion of IL-12 DNA as vaccine adjuvant.

Indexed as

Adjuvants, ImmunologicAnimalsElectroporationImmunity, HumoralInterleukin-12MacacaMacaca mulattaSAIDS VaccinesSimian Immunodeficiency VirusT-Lymphocytes, CytotoxicVaccines, DNAAdjuvants, ImmunologicInterleukin-12SAIDS VaccinesVaccines, DNAantibodyaviditycentral memoryeffector memoryHIVin vivo electroporationneutralizing antibodySIVmac239SIVsmE660transitional memory

Identifiers

PMID22894956
PMCPMC3601136
OpenAlexW2068414412

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.